Posts by viroger

The Drug Assessment Process: Inadequate and Costly

Posted on Wednesday, January 16, 2013

The more I study it, the more I believe the process of drug assessment by payers and providers needs some serious attention (we’ll pay plenty at the Real Endpoints Symposium, March 11-12). But driving...

Learn More

Payers, Churn & What It Means for Total Cost of Care

Posted on Tuesday, October 2, 2012

One question we get from pharmaceutical and diagnostic clients quite frequently: do payers really care about lowering the costs of care if the cost savings don’t show up for a few years?  The problem they’re...

Learn More

Drug Targeting & Reimbursability: It Ain’t Easy

Posted on Friday, January 6, 2012

All things being equal, insurers prefer a drug that’s designed to work for a person with a specific genotype than one targeting a more general group of patients. The notion makes sense medically. It should...

Learn More

Reimbursement as Environment

Posted on Monday, November 28, 2011

Who controls reimbursement? Talk to a drug company, or most pharmaceutical analysts, and the answer is payers.  Talk to payers and the answer is far more complicated – and not one where they claim overall...

Learn More

Healthcare’s Topeka Problem

Posted on Tuesday, November 22, 2011

You might have heard that, for about a month, domestic abusers in Topeka roamed free. Not because the community encourages wife-beaters.  But because it couldn’t afford to prosecute them.  County DAs, dealing...

Learn More